Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.42 |
| ▸ | METAP2 | P50579 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065184 | 0.80 | ALDH1A1 (0.42) | CTSDMETAP2CPB2METAP1ALDH1A1 | |
| SCHEMBL4069087 | 0.69 | METAP2 (0.45) | CTSDMETAP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4065205 | 0.68 | FFAR2 (0.37) | POLBMMP1MMP2MMP3KMT2A | |
| SCHEMBL4061716 | 0.68 | GRIK1 (0.31) | — | |
| SCHEMBL7682167 | 0.67 | MMP1 (0.41) | ALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL4071619 | 0.66 | — | — | |
| SCHEMBL2646813 | 0.65 | SLC6A3 (0.48) | METAP2METAP1 | |
| SCHEMBL2648622 | 0.65 | SLC6A3 (0.48) | METAP2METAP1 | |
| SCHEMBL7351333 | 0.65 | METAP2 (0.69) | CTSDMETAP2NPC1RAB9ACPB2 | |
| Hydrochloric Acid SCHEMBL7353291 | 0.65 | METAP2 (0.67) | CTSDMETAP2NPC1RAB9ACPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966443-B1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | CTSD 3667/4885METAP2 3568/4885NPC1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.